CAMBRIDGE, 12th February 2019 -
12th February 2019 - The co-founders of Cambridge Cancer Genomics (CCG.ai), a Y Combinator backed startup building the precision AI platform for personalised cancer medicine, were today named on Forbes’ annual 30 under 30 list, in the field of science and healthcare.
The european list, which has been running since 2016, names young disruptors making waves in their respective industries. CCG.ai’s Founders are named on the list alongside some incredible people and companies: from Faith Traeh, a doctor and medical advisor in Raqqa, Syria to the co-founders of Scewo, a group developing a self-balancing wheelchair that can climb stairs.
“I’m thrilled and truly humbled that myself, Evaline, Nirmesh & Harry made this year’s list. This is really testament to the team we have built at CCG.ai, we are only really only here to show off the work they do!” said Dr John Cassidy, CEO at CCG.ai
“I am incredibly grateful to have been named in this year’s list amongst such fantastic young achievers in business and science. Accolades like these motivate us to keep working hard to achieve our goal of improved cancer care for all.” said Dr Harry Clifford, CTO at CCG.ai
To see the rest of the list, visit:
About Cambridge Cancer Genomics
Cambridge Cancer Genomics (CCG.ai) is a Y Combinator backed startup building the underlying tools to empower oncologists to make the best therapeutic decisions for their patients. Their precision AI platform, OncOS, is fast becoming the global open standard for next generation sequencing analysis and clinical decision support in cancer medicine. By focussing on machine learning based analytics of serial liquid biopsy samples, CCG.ai is building predictive models to understand how tumours evolve and how this can impact on response to therapy. As this knowledge base of tumour genomic evolution increases, OncOS will become the operating system for personalised cancer medicine. At CCG.ai, our mission is to ensure every patient gets the right drug, at the right time, to beat their cancer.
For more details, or to request an interview, please contact: Press@CCG.ai